BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part …
Jetzt den vollständigen Artikel lesen